Maravai Life Sciences downgraded by Goldman with a new price target
$MRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $9.00 → $3.00 | Outperform → Neutral | Robert W. Baird |
| 12/19/2024 | Neutral | Guggenheim | |
| 12/5/2024 | $4.25 | Neutral → Sell | Goldman |
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 11/8/2024 | Outperform → Mkt Perform | William Blair | |
| 8/28/2024 | $10.00 | Overweight | Wells Fargo |
| 8/13/2024 | $11.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/10/2024 | $15.00 | Buy | Craig Hallum |